Clinical trialNCT03812510CompletedPhase 3Interventional

Safety Study of A-101 Topical Solution for the Treatment of Common Warts

SponsorAclaris Therapeutics, Inc.Enrollment426Common Wart

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

A Phase 3 Study of A-101 Topical Solution Applied Twice a Week in Subjects with Common Warts

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

David Gordon, MB, ChB
Aclaris Therapeutics
Study Director
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

46 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States

Aclaris Investigational Site
Mobile, Alabama, United States
Aclaris Investigational Site
Glendale, Arizona, United States
Aclaris Investigational Site
Fort Smith, Arkansas, United States
Aclaris Investigational Site
Hot Springs, Arkansas, United States
Aclaris Investigational Site
Encinitas, California, United States
Aclaris Investigational Site
Fountain Valley, California, United States
Aclaris Investigational Site
San Diego, California, United States
Aclaris Investigational Site
San Diego, California, United States
Aclaris Investigational Site
Denver, Colorado, United States
Aclaris Investigational Site
Aventura, Florida, United States
Aclaris Investigational Site
Jacksonville, Florida, United States
Aclaris Investigational Site
Miami, Florida, United States
Aclaris Investigational Site
Miami, Florida, United States
Aclaris Investigational Site
Ocala, Florida, United States
Aclaris Investigational Site
Newnan, Georgia, United States
Aclaris Investigational Site
Indianapolis, Indiana, United States
Aclaris Investigational Site
New Albany, Indiana, United States
Aclaris Investigational Site
Louisville, Kentucky, United States
Aclaris Investigational Site
Rockville, Maryland, United States
Aclaris Investigational Site
Fridley, Minnesota, United States
Aclaris Investigational Site
Saint Joseph, Missouri, United States
Aclaris Investigational Sites
Omaha, Nebraska, United States
Aclaris Investigational Site
Las Vegas, Nevada, United States
Aclaris Investigational Site
Verona, New Jersey, United States
Aclaris Investigational Site
Rochester, New York, United States
Aclaris Investigational Site
Raleigh, North Carolina, United States
Aclaris Investigational Site
Beachwood, Ohio, United States
Aclaris Investigational Site
Bexley, Ohio, United States
Aclaris Invesgational Site
Broomall, Pennsylvania, United States
Aclaris Investigational Site
Fort Washington, Pennsylvania, United States
Aclaris Investigational Site
Upper Saint Clair, Pennsylvania, United States
Aclaris Investigational Site
Anderson, South Carolina, United States
Aclaris Investigational Site
Charleston, South Carolina, United States
Aclaris Investigational Site
Fountain Inn, South Carolina, United States
Aclaris Investigational Site
Knoxville, Tennessee, United States
Aclaris Investigational Site
Nashville, Tennessee, United States
Aclaris Investigational Site
Arlington, Texas, United States
Aclaris Investigational Site
Austin, Texas, United States
Aclaris Investigational Site
College Station, Texas, United States
Aclaris Investigational Site
Houston, Texas, United States

6 more sites on the registry record.ClinicalTrials.gov ↗

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

A-101

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 7 Feb 2019
Primary completion: 27 Nov 2019
Completion: 20 Dec 2019
Last update posted: 23 Nov 2020
Registered enrollment: 426
Registry id: NCT03812510

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 4 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.